The COVID-19 pandemic has raised considerable concerns that patients with inflammatory
bowel disease (IBD), particularly those treated with immunosuppressive therapies, may …

Abstract Background and Aims Evidence suggests patients with inflammatory bowel disease
[IBD] receiving TNF antagonists have attenuated response to vaccination against COVID-19 …

Background The effects that therapies for inflammatory bowel disease (IBD) have on
immune responses to SARS-CoV-2 vaccination are not yet fully known. Therefore, we …

METHODS: In this prospective cohort of SARS-CoV-2 immunized patients with IBD, we
evaluated associations between participant age, sex, vaccine type, medication use, and the …

Objective Antitumour necrosis factor (anti-TNF) drugs impair protective immunity following
pneumococcal, influenza and viral hepatitis vaccination and increase the risk of serious …

Background Older age and comorbidities are the main risk factors for adverse COVID‐19
outcomes in patients with inflammatory bowel disease (IBD). The impact of IBD medications …

Background & Aims Studies have shown decreased response to coronavirus disease 2019
(COVID-19) vaccinations in some populations. In addition, it is possible that vaccine …

Background Patients with inflammatory bowel disease (IBD) on immune-modifying treatment
could be at an increased risk for severe coronavirus disease 2019 (COVID-19); thus, data on …

The COVID-19 pandemic has ushered a globally focused vaccine development program
that produced multiple successful vaccines within a year. Four SARS-CoV-2 vaccines have …

Immunization against the spike protein of SARS-CoV-2 reduces transmission 1, 2 and
severe outcomes. However, little is known regarding the impact of immune-mediated …